Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1399-1408

  Baeuerle, Patrick A ^a   Itin, Christian ^a  

^a Amgen Research GmbH   (Germany)

Author keywords

Bispecific antibody; Blinatumomab; Cancer therapy; Catumaxomab; CD3; Chimeric antigen receptor; Single chain antibody; T cell; T cell receptor; T body; Tumor associated antigen; Zeta chain

Indexed keywords

ANATUMOMAB MAFENATOX; BISPECIFIC ANTIBODY; BLINATUMOMAB; C REACTIVE PROTEIN; CATUMAXOMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; ERTUMAXOMAB; FBTA 05; GAMMA INTERFERON; GIRENTUXIMAB; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MT 110; NAPTUMOMAB ESTAFENATOX; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS ENTEROTOXIN B; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BODY WEIGHT; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CARCINOMATOUS PERITONITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIZZINESS; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATALITY; FATIGUE; FEVER; GENE THERAPY; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FAILURE; LUNG CANCER; LYMPHOCYTOPENIA; MALIGNANT ASCITES; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR REPROGRAMMING; OVARY CANCER; PROSTATE CANCER; RESPIRATORY DISTRESS SYNDROME; REVIEW; RIGOR; SIDE EFFECT; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THROMBOCYTOPENIA; TREMOR; VOMITING;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84858759304     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800785005     Document Type: Review

References (57)

1. Pagès, F.; Berger, A.; Camus, M.; Sanchez-Cabo, F.; Costes, A.; Molidor, R.; Mlecnik, B.; Kirilovsky, A.; Nilsson, M.; Damotte, D.; Meatchi, T.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H.; Galon, J. Effect or memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med., 2005, 353 (25), 2654-2666.
2. Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; Rubin, S.C.; Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med., 2003, 348 (3), 203-213.
3. Wahlin, B.E.; Sander, B.; Christensson, B.; Kimby, E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin. Cancer Res., 2007, 13 (2), 388-397.
4. Rabinovich, G.A.; Gabrilovich, D.; Sotomayor, E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol., 2007, 25, 267-296.
5. Renner, C.; Jung, W.; Sahin, U.; Denfeld, R.; Pohl, C.; Trümper, L.; Hartmann, F.; Diehl, V.; van Lier, R.; Pfreundschuh, M. Cure of xeno grafted human tumors by bispecific monoclonal antibodies and human T cells. Science, 1994, 264 (5160), 833-835.
6. Altenschmidt, U.; Klundt, E.; Groner, B. Adoptive transfer of invitro-targeted, activated lymphocytes results in total tumor regression. J. Immunol., 1997, 159 (11), 5509-5515.
7. Schlereth, B., Fichtner I.; Lorenczewski, G.; Kleindienst, P.; Brischwein, K.; Kufer, P.; Lutterbüse, R.; Wimberger, P.; Kimmig, R.; Baeuerle, P.A. Eradication of tumors from a human colon cancer cell line and primary ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res., 2005, 65 (7), 2882-2889.
8. Carpenito, C.; Milone, M.C.; Hassan, R.; Simonet, J.C.; Lakhal, M.; Suhoski, M.M.; Varela-Rohena, A.; Haines, K.M.; Heitjan, K.M.; Albelda, S.M.; Carroll, R.G.; Riley, J.L., Pastan, I.; June, C.H. Control of large, established tumor xenografts with genetically engineered human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. US, 2009, 106 (9), 3360-3365.
9. Morgan, R.A.; Dudley, M.E., Wunderlich, J.R.; Hughes, M.S.; Yang, J.C.; Sherry, R.M.; Royal, R.E.; Topalian, S.L.; Kammula, U.S.; Restifo, N.P.; Zheng, Z.; Nahvi, A.; de Vries, C.R.; Rogers-Freezer, L.J.; Mavroukakis, S.A.; Rosenberg, S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 2006, 314 (5796), 126-129.
10. Morse, M.A.; Whelan, M. A year of successful cancer vaccines points to a path forward. Curr. Opin. Mol. Ther., 2010, 12, 11-13.
11. Burges, A.; Wimberger, P.; Kümper, C.; Gorbounova, V.; Sommer, H.; Schmalfeldt, B.; Pfisterer, J.; Lichinitser, M.; Makhson, A.; Moiseyenko, V.; Lahr, A.; Schulze, E.; Jäger, M.; Ströhlein, M.A.; Heiss, M.M.; Gottwald, T.; Lindhofer, H.; Kimmig, R. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin. Cancer Res., 2007, 13 (13), 3899-3905.
12. Shaw, D.M.; Connolly, N.B.; Patel, P.M.; Kilany, S.; Hedlund, G.; Nordle, O.; Forsberg, G.; Zweit, J.; Stern, P.L. and Hawkins, R.E. A phase II study of a 5T4 oncofetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br. J. Cancer, 2007, 96 (4), 567-574.
13. Bargou, R.; Leo, E.; Zugmaier, G.; Goebeler, M.; Knop, S.; Noppeney, R.; Viardot, A.; Hess, G.; Schuler, M.; Einsele, H.; Riethmüller, G.; Brandl, C.; Wolf, A.; Kirchinger, P.; Klappers, P.; Schmidt, M.; Klinger, M.; Reinhardt, C.; Baeuerle, P.A. and Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 2008, 321 (5891), 974-977.
14. Urban, J.L.; Schreiber, H. Tumor antigens. Annu. Rev. Immunol., 1992, 10, 617-644.
15. Kurschus, F.C.; Fellows, E.; Stegmann, E. Jenne, D.E. Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc. Natl. Acad. Sci. USA, 2008, 105 (37), 13799-13804.
16. Purbhoo, M.A.; Irvine, D.J.; Huppa, J.B.; Davis M.M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 2004, 5 (5), 524-530.
17. Altenschmidt, U.; Moritz, D.; Groner, B. Specific cytotoxic Tlymphocytes in gene therapy. J. Mol. Med., 1997, 75 (4), 259-266.
18. Eshhar, Z. The T-body approach: redirecting T cells with antibody specificity. Handb. Exp. Pharmacol., 2008, 181, 329-342.
19. Marcu-Malina, V.; van Dorp, S.; Kuball, J. Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. Expert. Opin. Biol. Ther., 2009, 9 (5), 579-591.
20. Sadelain, M.; Brentjens, R.; Rivière, I. The promise and pitfalls of chimeric antigen receptors. Curr. Opin. Immunol., 2009, 21 (2), 215-223.
21. Bridgeman, J.S.; Hawkins, R.E.; Hombach, A.A.; Abken, H.; Gilham, D.E. Building better chimeric antigen receptors for adoptive T cell therapy. Curr. Gene Ther., 2010, 10 (2), 77-90.
22. Sommermeyer, D.; Neudorfer, J.; Weinhold, M.; Leisegang, M.; Engels, B.; Noessner, E.; Heemskerk, M.H.; Charo, J.; Schendel, D.J.; Blankenstein, T.; Bernhard, H.; Uckert, W. Designer T cells by T cell receptor replacement. Eur. J. Immunol., 2006, 36 (11), 3052-3059.
23. Zhao, Y.; Bennett, A.D.; Zheng, Z.; Wang, Q.J.; Robbins, P.F.; Yu, L.Y.; Li, Y.; Molloy, P.E.; Dunn, S.M.; Jakobsen, B.K.; Rosenberg, S.A. and Morgan, R.A. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol., 2007, 179 (9), 5845-5854.
24. Johnson, L.A.; Morgan, R.A.; Dudley, M.E.; Cassard, L.; Yang, J.C.; Hughes, M.S.; Kammula, U.S.; Royal, R.E.; Sherry, R.M.; Wunderlich, J.R.; Lee, C.C.; Restifo, N.P.; Schwarz, S, Cogdill, A.P.; Bishop, R.J.; Kim, H.; Brewer, C.C.; Rudy SF.; Van Waes, C.; Davis, J.L.; Mathur, A.; Ripley, R.T.; Nathan, D.A.; Laurencot, C.M.; Gene therapy with human and mouse T-cell receptors mediate cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009, 114 (3), 535-546.
25. Kershaw, M.H.; Westwood, J.A.; Parker, L.L.; Wang, G.; Eshhar, Z.; Mavroukakis, S.A,.; White, D.E.; Wunderlich, J.R.; Canevari, S.; Rogers-Freezer, L.; Chen, C.C.; Yang, J.C.; Rosenberg, S.A.; Hwu, P. A phase 1 study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin. Cancer Res., 2006, 12 (20), 6106-6115.
26. Lamers, C.H.J.; Sleijfer, S.; Vulto, A.G.; Kruit, W.H.J.; Kliffen, M.; Debets, R.; Gratama, J.W. Stoter, G. Treatment of meta static renal cell carcinoma with auto logous T-lymphovcytes genetically retargeted against carbonic an hydrase IX: First clinical experience. J. Clin. Oncol., 2006, 24 (13), e20-e22.
27. Lamers, C.H.J.; Langeveld, S.C.L.; Groot-van Ruijven, C.M.; Debets, R.; Sleijfer, S. Gratama, J.W. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene- specific immune functions in vivo. Cancer Immunol. Immunother., 2007, 56 (12), 1875-1883.
28. Brentjens, R.; Yeh, R.; Bernal, Y.; Riviere, I.; Sadelain, M. Treatment of chronic lymphocytic leukemia with genetically targeted auto logous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther., 2010, 18 (4), 666-668.
29. Porter, D.L.; Levine, B.L., Kalos, M., Bagg, A.; June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl. J. Med. 2011, 365 (8), 725-733.
30. Müller, D.; Kontermann, R.E. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr. Opin. Mol. Ther., 2007, 9 (4), 319-326.
31. Müller, D.; Kontermann, R.E. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs, 2010, 24 (2), 89-98.
32. Chames, P.; Baty, D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs, 2009, 1 (6), 539-547.
33. Minguet, S.; Schamel W.W. A permissive geometry model for TCR-CD3 activation. Trends Biochem. Sci., 2008, 33 (2), 51-57.
34. Brischwein, K., Parr, L.; Pflanz, S.; Volkland, J.; Lumsden, J.; Klinger, M.; Locher, M.; Hammond, S.; Kiener, P.; Schlereth, B.; Baeuerle, P.A. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother., 2007, 30 (8), 798-807.
35. Shen, J.; Zhu, Z. Catumaxomab a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr. Opin. Mol. Ther., 2008, 10 (3), 273-284.
36. De Gast, G.C.; Haagen, I.-A.; van Houten, A.A.; Klein, S.C.; Duits, A.J.; de Weger, R.A.; Vroom, T.M.; Clark, M.R.; Phillips, J.; van Dijk, A.J. CD8 T cell activation after intrvenous administration of CD3xCD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother., 1995, 40 (6), 390-396.
37. De Gast, G.C., van Houten, A.A.; Haagen, I.-A.; Klein, S.; de Weger, R.A.; van Dijk, A.; Phillips, J.; Clark M.; Bast, B.J.E.G. Clinical experience with CD3xCD19 bispecific antibodies in patienst with B cell malignancies. J. Hematotherapy, 1995, 4 (5), 433-437.
38. Buhmann, R.; Simoes, B.; Stanglmaier, M.; Yang, T.; Faltin, M.; Bund, D.; Lindhofer, H.; Kolb, H.J. Immunotherapy of recurrent Bcell malignancies after allo-SCT with Bi20 (FBTA05), a trin fucntional anti-CD3xanti-CD20 antibody with donor lymphocyte infusion. Bone Marrow Transplant., 2009, 43 (5), 383-397.
39. Linke, R.; Klein, A.; Seimetz, D. Catu maxomab: clinical development and future directions. Abs, 2010, 2 (2) [Epub ahead of print].
40. Seimetz, D.; Lindhofer, H.; Bokemeyer, C. Development and approval of the trifunctional antibody catumaxomab (anti- EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev., 2010 Mar 26 [EPub ahead of print].
41. Wimberger, P.; Heubner, M.; Lindhofer, H.; Jäger, M.; Kimmig, R.; Kasimir-Bauer, S. Influence of catu maxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res., 2009, 29 (8), 1787-1791.
42. Ströhlein, M.A.; Siegel, R.; Jäger, M.; Lindhofer, H; Jauch, K.W.; Heiss, M.M. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res., 2009, 28, 18.
43. Kiewe, P.; Hasmüller, S.; Kahlert, S.; Heinrigs, M.; Rack, B.; Marmé, A.; Korfel, A.; Jäger, M.; Lindhofer, H.; Sommer, H.; Thiel, M.; Untch, M. Phase I trial of the trifunctional anti-HER-2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin. Cancer Res., 2006, 12 (10), 3085-3091.
44. Robinson, M.K., Alpaugh, R.K.; Borghaei, H. Naptumomab estafenatox: a new immunoconjugate. Expert Opin. Biol. Ther., 2010, 10 (2), 273-279.
45. Cheng, J.D.; Babb, J.S.; Langer, C.; Aamdal, S.; Robert, F.; Engelhardt, L.R.; Fernberg, O.; Schiller, J.; Forsberg, G.; Alpaugh, R.K.; Wriner, L.M. and Rogatko, A. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J. Clin. Oncol., 2004, 22 (4), 602-609.
46. Borghaei, H.; Alpaugh, K.; Hedlund, G.; Forsberg, G.; Langer, C.; Rogatko, A.; Hawkins, R.; Dueland, S.; Lassen, U., Cohen, R.B. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 2009, 27 (25), 4116-4123.
47. Nagorsen, D., Bargou, R.; Ruettinger, D.; Kufer, P.; Baeuerle, P.A.; G. Zugmaier Immunotherapy of lymphoma and leukemia with T cell-engaging BiTE antibody blinatumomab. Leuk. Lymph., 2009, 50 (6), 1-6.
48. Baeuerle, P.A.; Reinhardt, C. Bispecific T cell engaging antibodies for cancer therapy. Cancer Res., 2009, 69 (12), 4941-4944.
49. Baeuerle, P.A.; Kufer, P.; Bargou, R. BiTE: Teaching antibodies to engage T cells. Curr. Opin. Mol. Ther., 2009, 11 (1), 22-30.
50. Goebeler, M.; Viardot, A.; Noppeney, R.; Krause, S.; Mackensen, A.; Rupertus, K.; Kanz, L.; Knop, S.; Topp, M.S.; Scheele, J.; Nagorsen, D.; Zugmaier, G.; Kufer, P.; Einsele, H.; Bargou, R. Blinatumomab (CD3/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkins lymphoma (NHL) including MCL and DLBCL. Ann. Oncol., 2011, 22 (suppl. 4), 105.
51. Topp, M.S.; Kufer, P; Goekbuet, N.; Goebeler, M.; Klinger, M.; Neumann, S.; Horst, H.A.; Raff, T.; Viardot, A.; Schmid, M.; Stelljes, M.; Schaich, M.; Degenhard, E.; Köhne-Volland, R.; Brüggemann, M.; Ottmann, O.G.; Pfeifer, H.; Burmeister, T.; Nagorsen, D.; Schmidt, M.; Lutterbuese, R.; Reinhardt, C.; Baeuerle, P.A.; Kneba, M.; Einsele, H.; Riethmueller, G.; Hoelzer, D.; Zugmaier, G.; Bargou, R.C. Targeted therapy with the T cell-engaging antibody blinatumomab of chemotherapy-refratcory minimal residual disease in B-lineage aute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol., 2011, 29(18), 2493-2498.
52. Topp, M.S.; Zugmaier, G.; Goekbuet, N.; Neumann, S.; Horst, H.A.; Raff, T.; Brüggemann, M.; Kneba, M.; Viardot, A.; Schmid, M.; Schaich, M.; Stelljes, M.; Goebeler, M.; Pfeifer, H.; Ottmann, O.G.; Burmeister, T.; Degenhard, E.; Schmidt, M.; Scheele, J.; Einsele, H.; Kufer, P.; Klinger, M.; Nagorsen, D.; Hoelzer, D. and Bargou, R.C. Treatment of patients with relapsed or refractory (r/r) B-ALL by blinatumomab. 16th Congress of the European Hematology Association, London, June 9-12, 2011, abstract 844.
53. Brischwein, K., Schlereth, B.; Guller, B.; Steiger, C.; Wolf, A.; Lutterbuese, R.; Offner, S.; Locher, M.; Urbig, T.; Raum, T.; Kleindienst, P.; Kimmig, R.; Fichtner, I.; Kufer, P.; da Silva, A.J.; Baeuerle, P.A. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating solid tumors. Mol. Immunol., 2006, 43 (8), 1129-1143.
54. Fiedler, W.; Hönemann, D.; Ritter, B.; Bokemeyer, C.; Seggewiß, R.; Fettes, P.; Klinger, M.; Vieser, E.; Kufer, P.; Reinhardt, C.; Baeuerle, P.A.; Schmidt, M.; Zugmaier, G.; Rüttinger, D.; Kaubitzsch, S.; Wolf, M. Safety and pharmacology of the Ep-CAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric or lung cancer. ECCO/ESMO Meeting Berlin, 2009, Abstract no. 1254.
55. Kieback, E.; Sommermeyer, C.J.; Blanckenstein, T.; Uckert, W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. USA, 2008, 105 (2), 623-628.
56. Kischel, R.; Hausmann, S.; Klinger, M.; Baeuerle, P.A.; Kufer, P. Effector memory T cells make a major contribution to redirected lysis by T cell-engaging BiTE antibody MT110. AACR Meeting Abstract, Apr., 2009, no. 3252.
57. Weber, J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother., 2009, 58 (8), 823-830